Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous CT-P13 in Moderately to Severely Active Rheumatoid Arthritis
NCT06738719Phase 3Completed
- Sponsor
- Celltrion
- Start
- Jan 2025
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing CT-P13 Auto-Injector with Placebo Auto-Injector (2 arms). Primary endpoint: American College of Rheumatology 20% improvement criteria at 12 weeks. Started Jan 2025; status: completed.
02
Drugs
infliximab-dyyb
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06738719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06738719.